Company profile

Anthony J. Cataldo
Incorporated in
Fiscal year end
Former names
Oxis International Inc
IRS number

OXIS stock data



14 Aug 19
22 Sep 19
31 Dec 19


Company financial data Financial data

Quarter (USD) Jun 19 Mar 19 Dec 18 Sep 18
Revenue 0
Net income -2.79M -4.51M -4.23M -235.78M
Diluted EPS -.05 -0.09 -0.07 -4.7
Operating income -2.28M -4.06M -3.09M -234.66M
Net change in cash 213K -9K -1.17M 136K
Cash on hand 264K 51K 60K 1.23M
Cost of revenue 0
Annual (USD) Dec 18 Dec 17 Dec 16 Dec 15
Revenue 0 0 0 27K
Net income -259.19M -144.17M 9.77M -21.46M
Diluted EPS -5.16 -8.6 119.91 -8.96
Net profit margin -79485%
Operating income -250.07M -135.57M -9.37M -8.93M
Net change in cash -516K 557K -28K -808K
Cash on hand 60K 576K 19K 47K
Cost of revenue 0 0 0 0

Financial data from company earnings reports

Financial report summary

PfizerInventiv HealthSanofiNantKwestPFE
  • Our business is at an early stage of development and we may not develop therapeutic products that can be commercialized.
  • We have a history of operating losses and we expect to continue to incur losses for the foreseeable future and we may never generate revenue or achieve profitability.
  • We will need additional capital to conduct our operations and develop our products, and our ability to obtain the necessary funding is uncertain.
  • Research and Development Investment
  • We have identified material weaknesses in our internal controls over financial reporting and have not yet remedied these weaknesses. If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, stockholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our common stock.
  • Our intellectual property may be compromised.
  • If our efforts to protect the proprietary nature of the intellectual property related to our technologies are not adequate, we may not be able to compete effectively in our market and our business would be harmed.
  • Claims that we infringe the intellectual property rights of others may prevent or delay our drug discovery and development efforts.
  • We may desire, or be forced, to seek additional licenses to use intellectual property owned by third parties, and such licenses may not be available on commercially reasonable terms or at all.
  • The patent protection covering some of our product candidates may be dependent on third parties, who may not effectively maintain that protection.
  • We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time- consuming and unsuccessful.
  • If we are unsuccessful in obtaining or maintaining patent protection for intellectual property in development, our business and competitive position would be harmed.
  • If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.
  • If we fail to meet our obligations under our license agreements, we may lose our rights to key technologies on which our business depends.
  • We will have to hire additional executive officers and employees to operate our business. If we are unable to hire qualified personnel, we may not be able to implement our business strategy.
  • We depend on key personnel for our continued operations and future success, and a loss of certain key personnel could significantly hinder our ability to move forward with our business plan.
  • We may be subject to claims by third parties asserting that our employees or we have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property.
  • Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could cause our business to suffer.
  • Our reliance on the activities of our non-employee consultants, research institutions and scientific contractors, whose activities are not wholly within our control, may lead to delays in development of our proposed products.
  • It may take longer to complete our clinical trials than we project, or we may not be able to complete them at all.
  • Clinical drug development is costly, time-consuming and uncertain, and we may suffer setbacks in our clinical development program that could harm our business.
  • If we experience delays or difficulties in the enrollment of patients in clinical trials, those clinical trials could take longer than expected to complete and our receipt of necessary regulatory approvals could be delayed or prevented.
  • We have limited clinical testing and regulatory capabilities, and human clinical trials are subject to extensive regulatory requirements, very expensive, time-consuming and difficult to design and implement. Our products may fail to achieve necessary safety and efficacy endpoints during clinical trials, which may limit our ability to generate revenues from therapeutic products.
  • We are subject to extensive regulation, which can be costly and time consuming and can subject us to unanticipated delays. even if we obtain regulatory approval for some of our products, those products may still face regulatory difficulties.
  • Obtaining regulatory approval even after clinical trials that are believed to be successful is an uncertain process.
  • We will continue to be subject to extensive FDA regulation following any product approvals, and if we fail to comply with these regulations, we may suffer a significant setback in our business.
  • Many of our business practices are subject to scrutiny and potential investigation by regulatory and government enforcement authorities, as well as to lawsuits brought by private citizens under federal and state laws. We could become subject to investigations, and our failure to comply with applicable law or an adverse decision in lawsuits may result in adverse consequences to us. If we fail to comply with U.S. healthcare laws, we could face substantial penalties and financial exposure, and our business, operations and financial condition could be adversely affected.
  • Laws impacting the U.S. healthcare system are subject to a great deal of uncertainty, which may result in adverse consequences to our business.
  • We may not be successful in our efforts to build a pipeline of product candidates.
  • Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any.
  • We may expend our limited resources to pursue a particular product candidate or indication that does not produce any commercially viable products and may fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.
  • Our products may be expensive to manufacture, and they may not be profitable if we are unable to control the costs to manufacture them.
  • We currently lack manufacturing capabilities to produce our therapeutic product candidates at commercial-scale quantities and do not have an alternate manufacturing supply, which could negatively impact our ability to meet any future demand for the product.
  • To be successful, our proposed products must be accepted by the healthcare community, which can be very slow to adopt or unreceptive to new technologies and products.
  • Our business is based on novel technologies that are inherently expensive and risky and may not be understood by or accepted in the marketplace, which could adversely affect our future value.
  • Our competition includes fully integrated biotechnology and pharmaceutical companies that have significant advantages over us.
  • If competitors develop and market products that are more effective, safer or less expensive than our product candidates or offer other advantages, our commercial prospects will be limited.
  • If we are unable to keep up with rapid technological changes in our field or compete effectively, we will be unable to operate profitably.
  • We may not be able to obtain third-party patient reimbursement or favorable product pricing, which would reduce our ability to operate profitably.
  • We may be subject to litigation that will be costly to defend or pursue and uncertain in its outcome.
  • We are exposed to the risk of liability claims, for which we may not have adequate insurance.
  • We could be subject to product liability lawsuits based on the use of our product candidates in clinical testing or, if obtained, following marketing approval and commercialization. If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to cease clinical testing or limit commercialization of our product candidates.
  • We rely on third parties to conduct preclinical and clinical trials of our product candidates. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed.
  • We contract with third parties for the supply of product candidates for clinical testing and expect to contract with third parties for the manufacturing of our product candidates for large-scale testing and commercial supply. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.
  • We currently have no marketing and sales force. If we are unable to establish effective marketing and sales capabilities or enter into agreements with third parties to market and sell our product candidates, we may not be able to effectively market and sell our product candidates, if approved, or generate product revenues.
  • Our business and operations would suffer in the event of system failures.
  • Our operations are vulnerable to interruption by natural disasters, power loss, terrorist activity and other events beyond our control, the occurrence of which could materially harm our business.
  • We have not held regular annual meetings in the past, and if we are required by the Delaware Court of Chancery to hold an annual meeting pursuant to Section 211(c) of the Delaware General Corporation Law, or the DGCL, it could result in the unanticipated expenditure of funds, time and other Company resources.
  • There has been a limited public market for our common stock, and we do not know whether one will develop to provide you adequate liquidity. Furthermore, the trading price for our common stock, should an active trading market develop, may be volatile and could be subject to wide fluctuations in per-share price.
  • Because our common stock may be deemed a low-priced “penny” stock, an investment in our common stock should be considered high- risk and subject to marketability restrictions.
  • If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline.
  • Anti-takeover provisions may limit the ability of another party to acquire us, which could cause our stock price to decline.
  • We do not currently or for the foreseeable future intend to pay dividends on our common stock.
Management Discussion
  • During the three months ended June 30, 2019 and 2018, we incurred $.2 million and $3.3 million of research and development expenses. Research and development costs decreased due primarily to the reductions employees, consultants and preclinical expenses. We anticipate our direct clinical costs to increase in second half of 2019 upon the initiation of a phase one clinical trial of our most advanced TriKe product candidate, OXS-3550.
  • During the three months ended June 30, 2019 and 2018, we incurred $2.1 million and $1.9 million of selling, general and administrative expenses.  The increase in selling, general and administrative expenses is primarily attributable the settlement of preferred shares.
  • Interest expense was $.5 million and $3.9 million for the three months ended June 30, 2019 and 2018 respectively.  The decrease is primarily due to a decrease related to the amortization of the original issue discount and beneficial conversion features related to various financing.
Content analysis ?
H.S. junior Bad
New words: Ali, CFO, confidentiality, cooperation, discovered, lieu, payroll, release, situation
Removed: amending, consistent, consulting, derivative, entity, model